Ranibizumab

Resumen

Alternativas con registro en Colombia

• Aflibercept · costo anual estimado $ 139.548.990
• Faricimab

Estudios clínicos principales

• FLUID: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or
  Fase 4 · 2013 · 349 participantes · Novartis Pharmaceuticals · NCT01972789
• Archway: A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macula
  Fase 3 · 2018 · 415 participantes · Hoffmann-La Roche · NCT03677934
• PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and P
  Fase 3 · 2020 · 174 participantes · Hoffmann-La Roche · NCT04503551
• Pagoda: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Com
  Fase 3 · 2019 · 672 participantes · Hoffmann-La Roche · NCT04108156

Enfermedades relacionadas

• Diabetes
• Degeneración macular y retinopatía

Fuentes

• Etiqueta FDA (DailyMed): CIMERLI
• EMA: Lucentis
• EMA: Byooviz